Table 3.
Effect on sex hormones
| Study Group | No. of Studies/subgroups | Heterogeneity | Effects Estimate(95% CI) | P Value |
|---|---|---|---|---|
| TT (SMD) | 10 | P < 0.001, I2 = 77.3% | -0.39 (-0.78, -0.002) | P = 0.049 |
| GLP1RA + MET vs MET | 3 | P = 0.008, I2 = 79.4% | -0.63 (-1.81, 0.55) | P = 0.293 |
| GLP1RA vs MET | 7 | P = 0.009, I2 = 65% | -0.15 (-0.53, 0.24) | P = 0.465 |
| GLP1RA vs Placebo | 2 | P = 0.001, I2 = 90.2% | -1.02 (-2.27, -0.23) | P = 0.110 |
| fT(SMD) | 5 | P = 0.102, I2 = 45.5% | -0.16 (-0.59, 0.27) | P = 0.463 |
| GLP1RA + MET vs MET | 2 | P = 0.671, I2 = 0% | -0.23 (-0.83, 0.36) | P = 0.444 |
| GLP1RA vs MET | 3 | P = 0.109, I2 = 54.8% | 0.16 (-0.57, 0.89) | P = 0.665 |
| GLP1RA vs Placebo | 1 | Not Applicable | -0.66 (-1.19, -0.13) | P = 0.015 |
| DHEAS (SMD) | 7 | P = 0.002, I2 = 67.1% | -0.40 (-0.82, 0.01) | P = 0.058 |
| GLP1RA + MET vs MET | 2 | P = 0.375, I2 = 0% | -0.76 (-1.44, -0.08) | P = 0.029 |
| GLP1RA vs MET | 6 | P = 0.557, I2 = 0% | -0.08 (-0.35, 0.18) | P = 0.542 |
| GLP1RA vs Placebo | 1 | Not Applicable | -1.43 (-1.99, -0.87) | P < 0.001 |
| SHBG (WMD) | 9 | P = 0.099, I2 = 37.5% | 4.42 (2.18, 6.67) | P < 0.001 |
| GLP1RA + MET vs MET | 3 | P = 0.665, I2 = 0% | 10.19 (6.29, 14.09) | P < 0.001 |
| GLP1RA vs MET | 7 | P = 0.203, I2 = 29.5% | 3.07 (0.63, 5.51) | P = 0.014 |
| GLP1RA vs Placebo | 1 | Not Applicable | 5.40 (-0.25, 11.05) | P = 0.061 |
| FAI(WMD) | 7 | P = 0.019, I2 = 58.4% | -1.55 (-2.59, -0.51) | P = 0.004 |
| GLP1RA + MET vs MET | 1 | Not Applicable | -3.50 (-5.39, -1.61) | P < 0.001 |
| GLP1RA vs MET | 5 | P = 0.037, I2 = 60.8% | -0.04 (-2.41, 2.32) | P = 0.973 |
| GLP1RA vs Placebo | 2 | P = 0.570, I2 = 0% | -1.74 (-2.05, -1.43) | P < 0.001 |